Critical care therapeutics market expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019

1
Critical Care Therapeutics in Major Developed
Markets to 2020 New and Late-Stage
Four-Factor PCCs and Recombinant Products to
Drive Market
Published on July 2014 No. of Pages 72
Reports and Intelligence
2
Description
Critical Care Therapeutics in Major Developed
Markets to 2020 - New and Late-Stage Four-Factor
PCCs and Recombinant Products to Drive Market
Summary GBI Research, the leading business
intelligence provider, has released its latest
research Critical Care Therapeutics in Major
Developed Markets to 2020 - New and Late-Stage
Four-Factor PCCs and Recombinant Products to
Drive Market, which provides in-depth analysis
of the critical care market in the US, UK,
France, Germany, Italy, Spain, Japan and
Canada. The report provides an estimation of
market size for 2013, along with market forecasts
to 2020. It covers critical care indications that
are being treated using the five major
plasma-derived products of albumin, anti-thrombin
concentrates, factor XIII concentrates,
fibrinogen concentrates, and prothrombin complex
concentrates. The total value of the critical
care market in the major developed markets was
estimated at 1.8 billion in 2013 and is expected
to grow at a Compound Annual Growth Rate (CAGR)
of 4.7 to 2.5 billion in 2019. This growth is
attributed to the recent approval of new factor
concentrates in the US that are expected to
witness increasing uptake in the forecast period.
3
Report Includes

• A brief introduction to the five major
  plasma-derived products in critical care and the
  indications that they are being used to treat, as
  well as disease overview, epidemiology, other
  treatment options, and treatment patterns
• Analysis of major marketed products in critical
  care, covering product performance in terms of
  the safety and efficacy of recent approvals
• A review of the critical care pipeline, including
  individual analysis of promising late-stage
  pipeline drugs that are most likely to enter the
  market during the forecast period
• Multi-scenario forecasts of the critical care
  market over the 20132020 period in the eight
  major developed markets
• Key drivers and restraints that have had and are
  expected to have a significant impact on the
  market

4
Reasons To Buy

• Align your product portfolio to markets with high
  growth potential
• Develop market entry and expansion strategies by
  identifying the regions and therapeutic segments
  poised for strong growth
• Devise effective, tailored strategies for each
  country through the understanding of key drivers
  and barriers in the critical care drugs market
• Develop key strategic initiatives based on an
  understanding of key focus areas and leading
  companies
• Accelerate and strengthen your market position by
  identifying key companies for mergers,
  acquisitions and strategic partnerships

5
Scope Of Report

• A brief introduction to the five major
  plasma-derived products in critical care and the
  indications that they are being used to treat, as
  well as disease overview, epidemiology, other
  treatment options, and treatment patterns
• Analysis of major marketed products in critical
  care, covering product performance in terms of
  the safety and efficacy of recent approvals
• A review of the critical care pipeline, including
  individual analysis of promising late-stage
  pipeline drugs that are most likely to enter the
  market during the forecast period
• Multi-scenario forecasts of the critical care
  market over the 20132020 period in the eight
  major developed markets
• Key drivers and restraints that have had and are
  expected to have a significant impact on the
  market

6
Get access to detailed information at
http//www.reportsandintelligence.com/critical-car
e-therapeutics-in-major-developed-to-2020-new-and-
late-stage-four-factor-pccs-and-recombinant-produc
ts-to-drive-market Enquire about report at
http//www.reportsandintelligence.com/enquire-abo
ut-report/132451